References
- Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13(Suppl 1):S47–9. doi:10.1016/0264-410X(95)80050-N. PMID:7571830
- World Health Organization. Global hepatitis Report, 2017 [accessed 2017 Sep 15] http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
- WHO global health estimated for 2015 published in 2016 (Global Health Estimates 2015: deaths by cause, age, sex, by country and region, 2000–2015. http://www.who.int/entity/healthinfo/global_burden_disease/GHE2015_Deaths_Global_2000_2015.xls?ua=1.
- Bodihar NP. Hepatitis B infection in pregnancy. Hepatitis B. Annual. 2004;1:199–209.
- World Health Organization. Hepatitis B vaccines: WHO position paper—July 2017. Weekly epidemiological record. 2017;92:369–92. PMID:28685564
- Centers for Disease Control and Prevention. Surveillance for Acute Viral Hepatitis —United States, 2007. MMWR. 2009;58(SS-3).
- Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179(2):489–92. doi:10.1086/314578. PMID:9878036
- Petousis-Harris H. Vaccine injection technique and reactogenicity-Evidence for practice. Vaccine. 2008;26(50):6299–304. doi:10.1016/j.vaccine.2008.08.052. PMID:18804137
- Cook IF. Evidence based route of administration of vaccines. Hum Vaccin. 2008;4(1):67–73. doi:10.4161/hv.4.1.4747. PMID:17881890
- Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin. 2009;5(2):92–7. doi:10.4161/hv.5.2.6587. PMID:18690015
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211. PMID:4023479